Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Manisha Prajapat and Bikash Medhi.
Manisha Prajapat
Connection Strength
6.587
Bikash Medhi
  1. Update on geographical variation and distribution of SARS-nCoV-2: A systematic review. Indian J Pharmacol. 2021 Jul-Aug; 53(4):310-316.
    View in: PubMed
    Score: 0.954
  2. Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2. J Mol Graph Model. 2020 12; 101:107716.
    View in: PubMed
    Score: 0.899
  3. Update on the target structures of SARS-CoV-2: A systematic review. Indian J Pharmacol. 2020 Mar-Apr; 52(2):142-149.
    View in: PubMed
    Score: 0.885
  4. Drug targets for corona virus: A systematic review. Indian J Pharmacol. 2020 Jan-Feb; 52(1):56-65.
    View in: PubMed
    Score: 0.871
  5. Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review. Indian J Pharmacol. 2021 Jul-Aug; 53(4):317-327.
    View in: PubMed
    Score: 0.238
  6. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review. Eur J Pharmacol. 2021 Sep 05; 906:174233.
    View in: PubMed
    Score: 0.237
  7. Structural and conformational analysis of SARS CoV 2 N-CTD revealing monomeric and dimeric active sites during the RNA-binding and stabilization: Insights towards potential inhibitors for N-CTD. Comput Biol Med. 2021 07; 134:104495.
    View in: PubMed
    Score: 0.236
  8. Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings. J Biomol Struct Dyn. 2021 May 13; 1-11.
    View in: PubMed
    Score: 0.236
  9. Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable? Med Hypotheses. 2021 Apr; 149:110539.
    View in: PubMed
    Score: 0.233
  10. Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for SARS-CoV-2: a systematic review. Tissue Cell. 2021 Jun; 70:101497.
    View in: PubMed
    Score: 0.232
  11. Indian contribution toward biomedical research and development in COVID-19: A systematic review. Indian J Pharmacol. 2021 Jan-Feb; 53(1):63-72.
    View in: PubMed
    Score: 0.230
  12. Efficacy and safety of steroid therapy in COVID-19: A rapid systematic review and Meta-analysis. Indian J Pharmacol. 2020 Nov-Dec; 52(6):535-550.
    View in: PubMed
    Score: 0.228
  13. In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations. mSystems. 2020 Sep 22; 5(5).
    View in: PubMed
    Score: 0.226
  14. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Indian J Pharmacol. 2020 Jul-Aug; 52(4):313-323.
    View in: PubMed
    Score: 0.223
  15. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain). J Biomol Struct Dyn. 2021 05; 39(8):2724-2732.
    View in: PubMed
    Score: 0.221
  16. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol. 2020 07; 92(7):776-785.
    View in: PubMed
    Score: 0.220
  17. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol. 2020 Jan-Feb; 52(1):1-5.
    View in: PubMed
    Score: 0.218
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.